BPA Call HT001414A0004-0016

Award Date 10/13/16
Potential Completion Date 9/30/17
Potential Value $646K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Charlotte, NC 28273, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price BPA call awarded by the Defense Health Agency (DHA) to TDS Med, Inc., a self-certified small disadvantaged business, to provide shortage pharmaceuticals, blood products, oncological products, injectables, orals, and medical inhalations. The $264,000 contract has an ultimate completion date of September 30, 2019. TDS Med, Inc. is an active federal contractor, holding a $2 million Blanket Purchase Agreement with the DHA to provide pharmaceutical products and supplies...
This is a firm fixed-price contract awarded by the Bureau of Medicine and Surgery, a component of the Department of Defense, to TDS Med, Inc., a self-certified small disadvantaged business. The contract is for $150,000.00 to provide pharmaceutical shortage supplies, including blood products, medical inhalations, injectables, and other relevant pharmaceutical products. This is a Blanket Purchase Agreement (BPA) call order that falls under a larger $2 million BPA awarded to TDS Med, Inc. in...
This federal contract award to TDS Med, Inc., a self-certified small disadvantaged business, was issued by the Defense Health Agency. The $300,000.00 contract is a Blanket Purchase Agreement (BPA) call to provide a variety of pharmaceutical products, including blood products, oncological pharmaceuticals, injectables, orals, and medical inhalations to address shortages. The contract has a period of performance through March 31, 2018 and uses a firm fixed-price pricing type. This BPA is part of...
This is a firm fixed-price Blanket Purchase Agreement (BPA) award to TDS Med, Inc., a small disadvantaged business, by the Defense Health Agency (DHA) for pharmaceutical products. The contract has a ceiling value of $150,000.00 and a period of performance through September 30, 2015. This BPA is part of a larger $2 million IDV (Indefinite Delivery Vehicle) contract awarded to TDS Med, Inc. in September 2019 to provide shortage pharmaceuticals, blood products, medical inhalations, injectables, and...
This is a firm fixed-price Blanket Purchase Agreement (BPA) call awarded by the Department of Defense's Bureau of Medicine and Surgery to TDS Med, Inc., a self-certified small disadvantaged business, to provide various pharmaceutical products. The $250,000 award has an ultimate completion date of September 30, 2015. TDS Med, Inc. has provided pharmaceutical products and medical supplies in support of COVID-19 response efforts and to address shortages for the Defense Health Agency and...
This is a firm fixed-price Blanket Purchase Agreement (BPA) call contract awarded by the Defense Health Agency (DHA) to TDS Med, Inc., a self-certified small disadvantaged business, to provide pharmaceutical supplies and drugs for the Walter Reed National Military Medical Center (WRNMMC). The $300,000 contract has an ultimate completion date of September 30, 2015 and was awarded on June 30, 2015. TDS Med, Inc. is an active federal contractor that has previously supported COVID-19 response...
This is a firm fixed price contract awarded by the Defense Health Agency (DHA) to The Compounding Center Inc., a minority-owned, self-certified small disadvantaged business. The $300,000 contract provides the DHA with a variety of pharmaceutical products, including blood products, oncology drugs, and other injectable, oral, and inhalation medications to address shortages impacting patient care at military and civilian treatment facilities. The contract is structured as a Blanket Purchase...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $294,150.00 and provides a range of pharmaceutical products and medical supplies to support military treatment facilities worldwide. This order was issued against an existing indefinite delivery contract with DLA Troop Support Medical, which has a potential value up to $5 million through...
This is a $1,318.59 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract supports the supply of 4567115025 ! DT 1C 2.25X4 700/RL 6RL/BX DHAPCL medical products, with a period of performance through February 3, 2025. The contract is not set aside and is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA...
The Defense Health Agency awarded a firm fixed price blanket purchase agreement (BPA) call to The Compounding Center Inc., a minority-owned, self-certified small disadvantaged business, to provide prescription pharmaceuticals such as vinblastine, carimune, and oncological medications. The $250,000 contract has no set-aside designation and supports the urgent needs of military treatment facilities, including Walter Reed National Military Medical Center, by delivering specialized, customized...

This is a $646,300 Firm Fixed Price Blanket Purchase Agreement (BPA) call contract awarded by the Defense Health Agency (DHA) to TDS Med, Inc., a small disadvantaged business. The contract is for the provision of various pharmaceutical shortage items, including blood products, oncological pharmaceuticals, and other injectable, oral, and inhalation medications. This contract does not have a set-aside designation. TDS Med, Inc. is an experienced federal contractor, having previously provided pharmaceutical products and COVID-19 response supplies to DHA and other agencies. The BPA was initially awarded in September 2019 with a 5-year period of performance, and this call order was placed in October 2016 to fulfill specific pharmaceutical shortage requirements.

Generated 7/27/24, 9:55 AM